Comparative Pharmacology
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus PEPTAVLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus PEPTAVLON.
MERETEK UBT KIT (W/ PRANACTIN) vs PEPTAVLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meretek UBT Kit contains [13C]urea; Helicobacter pylori urease hydrolyzes [13C]urea to produce [13C]CO2, which is detected in breath to indicate active H. pylori infection.
Peptavlon is a synthetic analogue of human parathyroid hormone (PTH 1-34) that acts as a diagnostic agent by stimulating osteoblast activity and increasing serum calcium levels through PTH receptor activation.
75 mg oral pranactin (citric acid) dissolved in 200 mL water, administered once for urea breath test.
Intravenous: 0.5 mg/kg every 6 hours; maximum single dose 40 mg.
None Documented
None Documented
Not applicable; 13C is a stable isotope that is rapidly converted to 13CO2; elimination half-life of CO2 from the body is approximately 5-10 minutes under normal respiratory conditions. Clinical context: 13CO2 appearance in breath peaks at 30 minutes post-dose.
Terminal elimination half-life: 8 hours (range 6-10 hours) in adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Urea (13C) is rapidly hydrolyzed by H. pylori urease in the stomach to 13CO2, which is absorbed and exhaled via the lungs; >99% of the 13C dose is eliminated as exhaled 13CO2 within 24 hours. Pranactin (citric acid) is metabolized to CO2 and water; <2% renal elimination.
Renal: 65% (unchanged), Biliary: 25% (metabolites), Fecal: 10%
Category C
Category C
Diagnostic Agent
Diagnostic Agent